Error in Author Affiliations and Supplement

No authors listed

Published Erratum

No authors listed. JAMA Oncol. 2021.

. 2021 Nov 1;7(11):1729.

doi: 10.1001/jamaoncol.2021.6304.

No abstract available

Erratum for

Fulvestrant-Palbociclib vs Letrozole-Palbociclib as Initial Therapy for Endocrine-Sensitive, Hormone Receptor-Positive, ERBB2-Negative Advanced Breast Cancer: A Randomized Clinical Trial.
Llombart-Cussac A, Pérez-García JM, Bellet M, Dalenc F, Gil-Gil M, Ruíz-Borrego M, Gavilá J, Sampayo-Cordero M, Aguirre E, Schmid P, Marmé F, Di Cosimo S, Gligorov J, Schneeweiss A, Albanell J, Zamora P, Wheatley D, Martínez-de Dueñas E, Amillano K, Malfettone A, Cortés J; PARSIFAL Steering Committee and Trial Investigators. Llombart-Cussac A, et al. JAMA Oncol. 2021 Dec 1;7(12):1791-1799. doi: 10.1001/jamaoncol.2021.4301. JAMA Oncol. 2021. PMID: 34617955 Free PMC article. Clinical Trial.

1. Llombart-Cussac A, Pérez-García JM, Bellet M, et al. ; PARSIFAL Steering Committee and Trial Investigators . Fulvestrant-palbociclib vs letrozole-palbociclib as initial therapy for endocrine-sensitive, hormone receptor–positive, ERBB2-negative advanced breast cancer: a randomized clinical trial. JAMA Oncol. Published online October 7, 2021. doi:10.1001/jamaoncol.2021.4301 - DOI - PMC - PubMed